GlassScriptPhysician profile
Francis G Bell
NPI 1912437310
$11,422.50
in general payments reported to CMS, 2019-2025
66 companies · $5,251 in 2025
The $5,251 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.48 · 2020: $14.02 · 2021: $1,001 · 2022: $657 · 2023: $1,639 · 2024: $2,848 · 2025: $5,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,131 · Consulting Fee: $2,300 · Education: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,130.73 |
| Consulting Fee | $2,300.00 |
| Education | $306.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,874.25 | 2021-2025 | Opdivo, Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $706.74 | 2021-2025 | Enhertu, Imfinzi |
| Janssen Biotech, INC. | $671.57 | 2022-2025 | Erleada, Rybrevant, Tecvayli |
| Incyte Corporation | $526.30 | 2021-2025 | Jakafi, Monjuvi, Niktimvo |
| Novartis Pharmaceuticals Corporation | $445.55 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $408.24 | 2022-2025 | Keytruda, Lynparza, Reblozyl |
| Astellas Pharma US INC | $386.62 | 2023-2025 | Cresemba, Xospata, Vyloy |
| Pfizer INC. | $353.51 | 2020-2025 | |
| Exelixis INC. | $327.00 | 2024-2025 | Cabometyx |
| Genzyme Corporation | $315.08 | 2021-2025 | |
| Genentech USA, INC. | $269.49 | 2023-2025 | Venclexta, Polivy, Itovebi |
| Daiichi Sankyo INC. | $234.20 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Abbvie INC. | $210.37 | 2024-2025 | |
| Glaxosmithkline, LLC. | $198.96 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Celgene Corporation | $195.70 | 2023-2025 | Reblozyl, Opdualag |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $188.60 | 2024-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $168.48 | 2021-2024 | Iclusig, Alunbrig, Ninlaro |
| Beigene USA, INC. | $160.05 | 2021-2025 | Brukinsa |
| Emd Serono, INC. | $149.59 | 2021-2025 | Bavencio |
| Stemline Therapeutics INC. | $140.31 | 2023-2025 | Orserdu |
| Amgen INC. | $125.68 | 2021-2022 | |
| Genmab U.S., INC. | $123.88 | 2023-2025 | Epkinly, Tivdak |
| Seagen INC. | $114.13 | 2023 | Adcetris |
| Alexion Pharmaceuticals, INC. | $111.17 | 2021-2025 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $106.75 | 2021-2025 | Rezlidhia, Gavreto, Tavalisse |
| Deciphera Pharmaceuticals INC. | $104.43 | 2022-2025 | Qinlock, Tgct |
| Spectrum Pharmaceuticals INC. | $94.66 | 2024-2025 | Rolvedon |
| Pharmacosmos Therapeutics INC. | $90.14 | 2023-2024 | Monoferric, Cosela |
| Octapharma USA, INC. | $88.68 | 2024-2025 | Octagam Immune Globulin (Human), Panzyga |
| Array Biopharma INC | $75.58 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Jazz Pharmaceuticals INC. | $74.72 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $67.88 | 2024-2025 | Libtayo |
| Taiho Oncology, INC. | $64.14 | 2023-2024 | |
| Fresenius Kabi USA, LLC | $62.03 | 2025 | Stimufend |
| Blueprint Medicines Corporation | $60.88 | 2023 | Ayvakit |
| Lilly USA, LLC | $60.75 | 2024 | Jaypirca, Verzenio |
| Adaptive Biotechnologies Corporation | $58.65 | 2023-2024 | Clonoseq |
| Tersera Therapeutics LLC | $56.98 | 2023-2025 | Zoladex, Xermelo |
| Pharmacyclics LLC, An Abbvie Company | $56.05 | 2023 | Imbruvica |
| Morphosys, US INC. | $54.87 | 2021-2023 | Monjuvi |
| Sumitomo Pharma America, INC. | $52.33 | 2025 | Orgovyx |
| Sobi, INC | $50.78 | 2024-2025 | |
| Pharmaessentia USA Corporation | $49.84 | 2025 | Besremi |
| Janssen Scientific Affairs, LLC | $49.70 | 2022-2024 | Darzalex, Tecvayli, Talvey |
| Puma Biotechnology, INC. | $47.98 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $46.16 | 2023-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $45.30 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $44.75 | 2024-2025 | |
| Beone Medicines USA, INC. | $43.72 | 2025 | Tevimbra |
| Ipsen Biopharmaceuticals, INC | $38.89 | 2021-2022 | |
| Emmaus Medical, INC. | $37.31 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.12 | 2024-2025 | Gilotrif |
| Kite Pharma, INC. | $35.67 | 2025 | Yescarta |
| Karyopharm Therapeutics INC. | $32.37 | 2023-2025 | Xpovio |
| Acceleron Pharma, INC. | $29.45 | 2021 | |
| Apellis Pharmaceuticals, INC. | $28.08 | 2023-2024 | Empaveli |
| Legend Biotech USA INC. | $24.90 | 2025 | Carvykti |
| Geron Corporation | $21.29 | 2025 | Rytelo |
| Eisai INC. | $18.70 | 2024 | |
| Agios Pharmaceuticals, INC. | $16.72 | 2025 | Pyrukynd |
| Cumberland Pharmaceuticals, INC. | $15.77 | 2024 | Sancuso |
| Myriad Genetic Laboratories, INC. | $15.67 | 2024 | Precisetumor |
| Dova Pharmaceuticals | $15.07 | 2021 | |
| Dendreon Pharmaceuticals LLC | $15.00 | 2025 | Provenge |
| Servier Pharmaceuticals LLC | $13.79 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.